Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation

Ailing Liu, Shirong Li, Vera Donnenberg, Jing Fu, Susanne M. Gollin, Huihui Ma, Caisheng Lu, Donna B. Stolz, Markus Y. Mapara, Sara A. Monaghan, Suzanne Lentzsch

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The immunomodulatory drugs, lenalidomide and pomalidomide yield high response rates in multiple myeloma patients, but are associated with a high rate of thrombocytopenia and increased risk of secondary hematologic malignancies. Here, we demonstrate that the immunomodulatory drugs induce self-renewal of hematopoietic progenitors and upregulate megakaryocytic colonies by inhibiting apoptosis and increasing proliferation of early megakaryocytic progenitors via down-regulation of IKZF1. In this process, the immunomodulatory drugs degrade IKZF1 and subsequently down-regulate its binding partner, GATA1. This results in the decrease of GATA1 targets such as ZFPM1 and NFE2, leading to expansion of megakaryocytic progenitors with concomitant inhibition of maturation of megakaryocytes. The down-regulation of GATA1 further decreases CCND1 and increases CDKN2A expression. Overexpression of GATA1 abrogated the effects of the immunomodulatory drugs and restored maturation of megakaryocytic progenitors. Our data not only provide the mechanism for the immunomodulatory drugs induced thrombocytopenia but also help to explain the higher risk of secondary malignancies and long-term cytopenia induced by enhanced cell cycling and subsequent exhaustion of the stem cell pool.

Original languageEnglish (US)
Pages (from-to)1688-1697
Number of pages10
JournalHaematologica
Volume103
Issue number10
DOIs
StatePublished - Sep 30 2018

Fingerprint

Down-Regulation
Pharmaceutical Preparations
Thrombocytopenia
Megakaryocytes
Hematologic Neoplasms
Multiple Myeloma
Up-Regulation
Stem Cells
Apoptosis
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation. / Liu, Ailing; Li, Shirong; Donnenberg, Vera; Fu, Jing; Gollin, Susanne M.; Ma, Huihui; Lu, Caisheng; Stolz, Donna B.; Mapara, Markus Y.; Monaghan, Sara A.; Lentzsch, Suzanne.

In: Haematologica, Vol. 103, No. 10, 30.09.2018, p. 1688-1697.

Research output: Contribution to journalArticle

Liu, A, Li, S, Donnenberg, V, Fu, J, Gollin, SM, Ma, H, Lu, C, Stolz, DB, Mapara, MY, Monaghan, SA & Lentzsch, S 2018, 'Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation', Haematologica, vol. 103, no. 10, pp. 1688-1697. https://doi.org/10.3324/haematol.2018.188227
Liu, Ailing ; Li, Shirong ; Donnenberg, Vera ; Fu, Jing ; Gollin, Susanne M. ; Ma, Huihui ; Lu, Caisheng ; Stolz, Donna B. ; Mapara, Markus Y. ; Monaghan, Sara A. ; Lentzsch, Suzanne. / Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation. In: Haematologica. 2018 ; Vol. 103, No. 10. pp. 1688-1697.
@article{464d839939d346e8ac1069850612e7d8,
title = "Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation",
abstract = "The immunomodulatory drugs, lenalidomide and pomalidomide yield high response rates in multiple myeloma patients, but are associated with a high rate of thrombocytopenia and increased risk of secondary hematologic malignancies. Here, we demonstrate that the immunomodulatory drugs induce self-renewal of hematopoietic progenitors and upregulate megakaryocytic colonies by inhibiting apoptosis and increasing proliferation of early megakaryocytic progenitors via down-regulation of IKZF1. In this process, the immunomodulatory drugs degrade IKZF1 and subsequently down-regulate its binding partner, GATA1. This results in the decrease of GATA1 targets such as ZFPM1 and NFE2, leading to expansion of megakaryocytic progenitors with concomitant inhibition of maturation of megakaryocytes. The down-regulation of GATA1 further decreases CCND1 and increases CDKN2A expression. Overexpression of GATA1 abrogated the effects of the immunomodulatory drugs and restored maturation of megakaryocytic progenitors. Our data not only provide the mechanism for the immunomodulatory drugs induced thrombocytopenia but also help to explain the higher risk of secondary malignancies and long-term cytopenia induced by enhanced cell cycling and subsequent exhaustion of the stem cell pool.",
author = "Ailing Liu and Shirong Li and Vera Donnenberg and Jing Fu and Gollin, {Susanne M.} and Huihui Ma and Caisheng Lu and Stolz, {Donna B.} and Mapara, {Markus Y.} and Monaghan, {Sara A.} and Suzanne Lentzsch",
year = "2018",
month = "9",
day = "30",
doi = "10.3324/haematol.2018.188227",
language = "English (US)",
volume = "103",
pages = "1688--1697",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",

}

TY - JOUR

T1 - Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation

AU - Liu, Ailing

AU - Li, Shirong

AU - Donnenberg, Vera

AU - Fu, Jing

AU - Gollin, Susanne M.

AU - Ma, Huihui

AU - Lu, Caisheng

AU - Stolz, Donna B.

AU - Mapara, Markus Y.

AU - Monaghan, Sara A.

AU - Lentzsch, Suzanne

PY - 2018/9/30

Y1 - 2018/9/30

N2 - The immunomodulatory drugs, lenalidomide and pomalidomide yield high response rates in multiple myeloma patients, but are associated with a high rate of thrombocytopenia and increased risk of secondary hematologic malignancies. Here, we demonstrate that the immunomodulatory drugs induce self-renewal of hematopoietic progenitors and upregulate megakaryocytic colonies by inhibiting apoptosis and increasing proliferation of early megakaryocytic progenitors via down-regulation of IKZF1. In this process, the immunomodulatory drugs degrade IKZF1 and subsequently down-regulate its binding partner, GATA1. This results in the decrease of GATA1 targets such as ZFPM1 and NFE2, leading to expansion of megakaryocytic progenitors with concomitant inhibition of maturation of megakaryocytes. The down-regulation of GATA1 further decreases CCND1 and increases CDKN2A expression. Overexpression of GATA1 abrogated the effects of the immunomodulatory drugs and restored maturation of megakaryocytic progenitors. Our data not only provide the mechanism for the immunomodulatory drugs induced thrombocytopenia but also help to explain the higher risk of secondary malignancies and long-term cytopenia induced by enhanced cell cycling and subsequent exhaustion of the stem cell pool.

AB - The immunomodulatory drugs, lenalidomide and pomalidomide yield high response rates in multiple myeloma patients, but are associated with a high rate of thrombocytopenia and increased risk of secondary hematologic malignancies. Here, we demonstrate that the immunomodulatory drugs induce self-renewal of hematopoietic progenitors and upregulate megakaryocytic colonies by inhibiting apoptosis and increasing proliferation of early megakaryocytic progenitors via down-regulation of IKZF1. In this process, the immunomodulatory drugs degrade IKZF1 and subsequently down-regulate its binding partner, GATA1. This results in the decrease of GATA1 targets such as ZFPM1 and NFE2, leading to expansion of megakaryocytic progenitors with concomitant inhibition of maturation of megakaryocytes. The down-regulation of GATA1 further decreases CCND1 and increases CDKN2A expression. Overexpression of GATA1 abrogated the effects of the immunomodulatory drugs and restored maturation of megakaryocytic progenitors. Our data not only provide the mechanism for the immunomodulatory drugs induced thrombocytopenia but also help to explain the higher risk of secondary malignancies and long-term cytopenia induced by enhanced cell cycling and subsequent exhaustion of the stem cell pool.

UR - http://www.scopus.com/inward/record.url?scp=85054349965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054349965&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.188227

DO - 10.3324/haematol.2018.188227

M3 - Article

C2 - 29954930

AN - SCOPUS:85054349965

VL - 103

SP - 1688

EP - 1697

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -